{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T15:16:38Z","timestamp":1789917398695,"version":"4.0.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,6,15]],"date-time":"2019-06-15T00:00:00Z","timestamp":1560556800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,6,15]],"date-time":"2019-06-15T00:00:00Z","timestamp":1560556800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Diabetol"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1007\/s00592-019-01378-7","type":"journal-article","created":{"date-parts":[[2019,6,15]],"date-time":"2019-06-15T17:02:21Z","timestamp":1560618141000},"page":"71-80","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Myopathy with DPP-4 inhibitors and statins in the real world: investigating the likelihood of drug\u2013drug interactions through the FDA adverse event reporting system"],"prefix":"10.1007","volume":"57","author":[{"given":"Ippazio Cosimo","family":"Antonazzo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Poluzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Forcesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Salvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Pariente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulio","family":"Marchesini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"De Ponti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0487-7996","authenticated-orcid":false,"given":"Emanuel","family":"Raschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,15]]},"reference":[{"issue":"5","key":"1378_CR1","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1111\/j.1464-5491.2011.03502.x","volume":"29","author":"R Bhome","year":"2012","unstructured":"Bhome R, Penn H (2012) Rhabdomyolysis precipitated by a sitagliptin-atorvastatin drug interaction. Diabet Med 29(5):693\u2013694","journal-title":"Diabet Med"},{"key":"1378_CR2","doi-asserted-by":"publisher","first-page":"103","DOI":"10.2147\/IJGM.S98543","volume":"9","author":"MW Khan","year":"2016","unstructured":"Khan MW, Kurian S, Bishnoi R (2016) Acute-onset rhabdomyolysis secondary to sitagliptin and atorvastatin interaction. Int J Gen Med 9:103\u2013106","journal-title":"Int J Gen Med"},{"issue":"10","key":"1378_CR3","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1111\/j.1464-5491.2008.02536.x","volume":"25","author":"DP Kao","year":"2008","unstructured":"Kao DP, Kohrt HE, Kugler J (2008) Renal failure and rhabdomyolysis associated with sitagliptin and simvastatin use. Diabet Med 25(10):1229\u20131230","journal-title":"Diabet Med"},{"issue":"3","key":"1378_CR4","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1592\/phco.29.3.352","volume":"29","author":"RV DiGregorio","year":"2009","unstructured":"DiGregorio RV, Pasikhova Y (2009) Rhabdomyolysis caused by a potential sitagliptin-lovastatin interaction. Pharmacotherapy 29(3):352\u2013356","journal-title":"Pharmacotherapy"},{"key":"#cr-split#-1378_CR5.1","unstructured":"European Medicines Agency (2014) Vildagliptin"},{"key":"#cr-split#-1378_CR5.2","unstructured":"Vildagliptin, metformin-Rhabdomyolysis. In PRAC recommendations on signals. Adopted at the PRAC Meeting of 10-13 June 2014. London, U.K., European Medicines Agency, pp 8-9 [internet]. Available from:  http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/PRAC_recommendation_on_signal\/2014\/07\/WC500169486.pdf"},{"issue":"3","key":"1378_CR6","doi-asserted-by":"publisher","first-page":"253","DOI":"10.2165\/11586990-000000000-00000","volume":"34","author":"J Strandell","year":"2011","unstructured":"Strandell J, Caster O, Bate A, Noren N, Edwards IR (2011) Reporting patterns indicative of adverse drug interactions: a systematic evaluation in VigiBase. Drug Saf 34(3):253\u2013266","journal-title":"Drug Saf"},{"issue":"3","key":"1378_CR7","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1111\/dom.13130","volume":"20","author":"GP Fadini","year":"2018","unstructured":"Fadini GP, Bonora BM, Mayur S, Rigato M, Avogaro A (2018) Dipeptidyl peptidase-4 inhibitors moderate the risk of genitourinary tract infections associated with sodium-glucose co-transporter-2 inhibitors. Diabetes Obes Metab 20(3):740\u2013744","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"1378_CR8","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1007\/s13300-018-0408-2","volume":"9","author":"GP Fadini","year":"2018","unstructured":"Fadini GP, Sarangdhar M, Avogaro A (2018) Pharmacovigilance evaluation of the association between DPP-4 inhibitors and heart failure: stimulated reporting and moderation by drug interactions. Diabet Ther 9(2):851\u2013861","journal-title":"Diabet Ther"},{"issue":"3","key":"1378_CR9","doi-asserted-by":"publisher","first-page":"e27","DOI":"10.2337\/dc16-1822","volume":"40","author":"V Labat","year":"2017","unstructured":"Labat V, Arnaud M, Miremont-Salame G, Salvo F, Begaud B, Pariente A (2017) Risk of myopathy associated with DPP-4 inhibitors in combination with statins: a disproportionality analysis using data from the WHO and French spontaneous reporting databases. Diabet Care 40(3):e27\u2013e29","journal-title":"Diabet Care"},{"issue":"10","key":"1378_CR10","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1002\/pds.3503","volume":"22","author":"M Tarapues","year":"2013","unstructured":"Tarapues M, Cereza G, Figueras A (2013) Association of musculoskeletal complaints and gliptin use: review of spontaneous reports. Pharmacoepidemiol Drug Saf 22(10):1115\u20131118","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1378_CR11","doi-asserted-by":"publisher","DOI":"10.5772\/intechopen.79986","volume-title":"Pharmacovigilance","author":"Emanuel Raschi","year":"2019","unstructured":"Raschi E, Moretti U, Salvo F et al (2018) Evolving roles of spontaneous reporting systems to assess and monitor drug safety. In: Kothari CS, Shah M, Patel RM (eds) Pharmacovigilance. IntechOpen. \nhttps:\/\/doi.org\/10.5772\/intechopen.79986"},{"issue":"6","key":"1378_CR12","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.numecd.2018.02.014","volume":"28","author":"E Raschi","year":"2018","unstructured":"Raschi E, Poluzzi E, Salvo F, et al. (2018) Pharmacovigilance of sodium-glucose co-transporter-2 inhibitors: what a clinician should know on disproportionality analysis of spontaneous reporting systems. Nutr Metab Cardiovasc Dis 28(6):533\u2013542","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"1378_CR13","first-page":"265","volume-title":"Data mining applications in engineering and medicine","author":"E Poluzzi","year":"2012","unstructured":"Poluzzi E, Raschi E, Piccinni C, De Ponti F (2012) Data mining techniques in pharmacovigilance: analysis of the publicly accessible FDA adverse event reporting system (AERS). In: Karahoca A (ed) Data mining applications in engineering and medicine. InTech, Croatia, pp 265\u2013302"},{"issue":"12","key":"1378_CR14","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1002\/pds.4672","volume":"27","author":"C Fukazawa","year":"2018","unstructured":"Fukazawa C, Hinomura Y, Kaneko M, Narukawa M (2018) Significance of data mining in routine signal detection: analysis based on the safety signals identified by the FDA. Pharmacoepidemiol Drug Saf 27(12):1402\u20131408","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"1378_CR15","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/clpt.2013.24","volume":"93","author":"R Harpaz","year":"2013","unstructured":"Harpaz R, DuMouchel W, LePendu P, et al. (2013) Performance of pharmacovigilance signal-detection algorithms for the FDA adverse event reporting system. Clin Pharmacol Ther 93(6):539\u2013546","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"1378_CR16","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/pds.1742","volume":"18","author":"A Bate","year":"2009","unstructured":"Bate A, Evans SJ (2009) Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf 18(6):427\u2013436","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"7","key":"1378_CR17","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","volume":"10","author":"T Sakaeda","year":"2013","unstructured":"Sakaeda T, Tamon A, Kadoyama K, Okuno Y (2013) Data mining of the public version of the FDA adverse event reporting system. Int J Med Sci 10(7):796\u2013803","journal-title":"Int J Med Sci"},{"issue":"7","key":"1378_CR18","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s40264-014-0187-2","volume":"37","author":"H Geniaux","year":"2014","unstructured":"Geniaux H, Assaf D, Miremont-Salame G, Raspaud B, Gouverneur A, Robinson P et al (2014) Performance of the standardised MedDRA(R) queries for case retrieval in the French spontaneous reporting database. Drug Saf 37(7):537\u2013542","journal-title":"Drug Saf"},{"issue":"9\u201310","key":"1378_CR19","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s002280000215","volume":"56","author":"EP van Puijenbroek","year":"2000","unstructured":"van Puijenbroek EP, Egberts AC, Heerdink ER, Leufkens HG (2000) Detecting drug-drug interactions using a database for spontaneous adverse drug reactions: an example with diuretics and non-steroidal anti-inflammatory drugs. Eur J Clin Pharmacol 56(9\u201310):733\u2013738","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"1378_CR20","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1046\/j.1365-2125.1999.00957.x","volume":"47","author":"EP Van Puijenbroek","year":"1999","unstructured":"Van Puijenbroek EP, Egberts AC, Meyboom RH, Leufkens HG (1999) Signalling possible drug-drug interactions in a spontaneous reporting system: delay of withdrawal bleeding during concomitant use of oral contraceptives and itraconazole. Br J Clin Pharmacol 47(6):689\u2013693","journal-title":"Br J Clin Pharmacol"},{"issue":"11","key":"1378_CR21","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1002\/pds.3626","volume":"23","author":"Z Yue","year":"2014","unstructured":"Yue Z, Shi J, Jiang P, Sun H (2014) Acute kidney injury during concomitant use of valacyclovir and loxoprofen: detecting drug-drug interactions in a spontaneous reporting system. Pharmacoepidemiol Drug Saf 23(11):1154\u20131159","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"10","key":"1378_CR22","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1007\/s40264-017-0564-8","volume":"40","author":"A Capogrosso Sansone","year":"2017","unstructured":"Capogrosso Sansone A, Convertino I, Galiulo MT, et al. (2017) Muscular adverse drug reactions associated with proton pump inhibitors: a disproportionality analysis using the Italian national network of pharmacovigilance database. Drug Saf 40(10):895\u2013909","journal-title":"Drug Saf"},{"issue":"1","key":"1378_CR23","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","volume":"11","author":"EP van Puijenbroek","year":"2002","unstructured":"van Puijenbroek EP, Bate A, Leufkens HG, Lindquist M, Orre R, Egberts AC (2002) A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf 11(1):3\u201310","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"1378_CR24","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1111\/j.1365-2125.2007.02900.x","volume":"64","author":"BT Thakrar","year":"2007","unstructured":"Thakrar BT, Grundschober SB, Doessegger L (2007) Detecting signals of drug-drug interactions in a spontaneous reports database. Br J Clin Pharmacol 64(4):489\u2013495","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"1378_CR25","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s00592-011-0340-7","volume":"50","author":"E Raschi","year":"2013","unstructured":"Raschi E, Piccinni C, Poluzzi E, Marchesini G, De Ponti F (2013) The association of pancreatitis with antidiabetic drug use: gaining insight through the FDA pharmacovigilance database. Acta Diabetol 50(4):569\u2013577","journal-title":"Acta Diabetol"},{"issue":"8","key":"1378_CR26","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1007\/s00125-017-4301-8","volume":"60","author":"GP Fadini","year":"2017","unstructured":"Fadini GP, Bonora BM, Avogaro A (2017) SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA adverse event reporting system. Diabetologia 60(8):1385\u20131389","journal-title":"Diabetologia"},{"issue":"4","key":"1378_CR27","doi-asserted-by":"publisher","first-page":"315","DOI":"10.2165\/11596510-000000000-00000","volume":"35","author":"D Motola","year":"2012","unstructured":"Motola D, Piccinni C, Biagi C, et al. (2012) Cardiovascular, ocular and bone adverse reactions associated with thiazolidinediones: a disproportionality analysis of the US FDA adverse event reporting system database. Drug Saf 35(4):315\u2013323","journal-title":"Drug Saf"},{"issue":"6","key":"1378_CR28","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.2337\/dc10-2412","volume":"34","author":"C Piccinni","year":"2011","unstructured":"Piccinni C, Motola D, Marchesini G, Poluzzi E (2011) Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting. Diabet Care 34(6):1369\u20131371","journal-title":"Diabet Care"},{"issue":"7","key":"1378_CR29","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s40264-013-0063-5","volume":"36","author":"F Salvo","year":"2013","unstructured":"Salvo F, Leborgne F, Thiessard F, Moore N, Begaud B, Pariente A (2013) A potential event-competition bias in safety signal detection: results from a spontaneous reporting research database in France. Drug Saf 36(7):565\u2013572","journal-title":"Drug Saf"},{"key":"1378_CR30","doi-asserted-by":"publisher","first-page":"e3100","DOI":"10.1002\/dmrr.3100","volume":"35","author":"E Kalaitzoglou","year":"2018","unstructured":"Kalaitzoglou E, Fowlkes JL, Popescu I, Thrailkill KM (2018) Diabetes pharmacotherapy and effects on the musculoskeletal system. Diabet\/Metab Res Rev 35:e3100","journal-title":"Diabet\/Metab Res Rev"},{"issue":"4","key":"1378_CR31","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1080\/14740338.2018.1444027","volume":"17","author":"AJ Scheen","year":"2018","unstructured":"Scheen AJ (2018) The safety of gliptins: updated data in 2018. Expert Opin Drug Saf 17(4):387\u2013405","journal-title":"Expert Opin Drug Saf"},{"issue":"6","key":"1378_CR32","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1007\/s00592-018-1271-3","volume":"56","author":"G Sesti","year":"2019","unstructured":"Sesti G, Avogaro A, Belcastro S et al (2019) Ten years of experience with DPP-4 inhibitors for the treatment of type 2 diabetes mellitus. Acta Diabetol 56(6):605\u2013617","journal-title":"Acta Diabetol"},{"issue":"5","key":"1378_CR33","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s40264-016-0399-8","volume":"39","author":"A Mascolo","year":"2016","unstructured":"Mascolo A, Rafaniello C, Sportiello L, et al. (2016) Dipeptidyl Peptidase (DPP)-4 inhibitor-induced arthritis\/arthralgia: a review of clinical cases. Drug Saf 39(5):401\u2013407","journal-title":"Drug Saf"},{"issue":"2","key":"1378_CR34","doi-asserted-by":"publisher","first-page":"e2957","DOI":"10.1002\/dmrr.2957","volume":"34","author":"R Bouchi","year":"2018","unstructured":"Bouchi R, Fukuda T, Takeuchi T, et al. (2018) Dipeptidyl peptidase 4 inhibitors attenuates the decline of skeletal muscle mass in patients with type 2 diabetes. Diabet\/Metab Res Rev 34(2):e2957","journal-title":"Diabet\/Metab Res Rev"},{"issue":"10","key":"1378_CR35","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.jamda.2016.04.016","volume":"17","author":"MR Rizzo","year":"2016","unstructured":"Rizzo MR, Barbieri M, Fava I, et al. (2016) Sarcopenia in elderly diabetic patients: role of dipeptidyl peptidase 4 inhibitors. J Am Med Dir Assoc 17(10):896\u2013901","journal-title":"J Am Med Dir Assoc"},{"issue":"4","key":"1378_CR36","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1177\/0091270008330983","volume":"49","author":"AJ Bergman","year":"2009","unstructured":"Bergman AJ, Cote J, Maes A, et al. (2009) Effect of sitagliptin on the pharmacokinetics of simvastatin. J Clin Pharmacol 49(4):483\u2013488","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"1378_CR37","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.tips.2012.03.001","volume":"33","author":"A Tornio","year":"2012","unstructured":"Tornio A, Niemi M, Neuvonen PJ, Backman JT (2012) Drug interactions with oral antidiabetic agents: pharmacokinetic mechanisms and clinical implications. Trends Pharmacol Sci 33(6):312\u2013322","journal-title":"Trends Pharmacol Sci"},{"issue":"3","key":"1378_CR38","doi-asserted-by":"publisher","first-page":"147","DOI":"10.2165\/11598080-000000000-00000","volume":"51","author":"YL He","year":"2012","unstructured":"He YL (2012) Clinical pharmacokinetics and pharmacodynamics of vildagliptin. Clin Pharmacokinet 51(3):147\u2013162","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"1378_CR39","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1177\/0192623316672944","volume":"45","author":"P Hoffmann","year":"2017","unstructured":"Hoffmann P, Martin L, Keselica M, et al. (2017) Acute toxicity of Vildagliptin. Toxicol Pathol 45(1):76\u201383","journal-title":"Toxicol Pathol"},{"issue":"3","key":"1378_CR40","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1111\/bcp.12353","volume":"78","author":"H Schelleman","year":"2014","unstructured":"Schelleman H, Han X, Brensinger CM, et al. (2014) Pharmacoepidemiologic and in vitro evaluation of potential drug-drug interactions of sulfonylureas with fibrates and statins. Br J Clin Pharmacol 78(3):639\u2013648","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"1378_CR41","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1002\/cpt.297","volume":"99","author":"CE Leonard","year":"2016","unstructured":"Leonard CE, Bilker WB, Brensinger CM, et al. (2016) Severe hypoglycemia in users of sulfonylurea antidiabetic agents and antihyperlipidemics. Clin Pharmacol Ther 99(5):538\u2013547","journal-title":"Clin Pharmacol Ther"}],"container-title":["Acta Diabetologica"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-019-01378-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00592-019-01378-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-019-01378-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,16]],"date-time":"2020-09-16T14:05:54Z","timestamp":1600265154000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00592-019-01378-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,15]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["1378"],"URL":"https:\/\/doi.org\/10.1007\/s00592-019-01378-7","relation":{},"ISSN":["0940-5429","1432-5233"],"issn-type":[{"value":"0940-5429","type":"print"},{"value":"1432-5233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,15]]},"assertion":[{"value":"20 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"ICA, EP, EF, FS, AP, FDP and ER have no conflicts of interest relevant to the content of the present work. GM reports personal fees and other from Sanofi, personal fees and other from NOVO Nordisk, personal fees and other from Eli-Lilly, other from Astra Zeneca, other from Glaxo, personal fees and other from Janssen, outside the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"For this type of study, ethical approval is not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"For this type of study, formal consent is not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}}]}}